Home > News > AlphaMa and Viva Biotech Reached Cooperation Agreement on IntelligentDEL (iDEL) Screening Platform

AlphaMa and Viva Biotech Reached Cooperation Agreement on IntelligentDEL (iDEL) Screening Platform

POSTED ON 2020-12-21 BY zhaojunli

AlphaMa will cooperate with Viva Biotech to provide clients AI-based DNA Encoded compound library screening technology.

SHANGHAI, CHINA—-Recently, AlphaMa Biotech signed a new drug discovery technology cooperation agreement with Viva Biotech Co., Ltd. (hereinafter referred to as ” Viva”). According to the agreement, AlphaMa will cooperate with Viva Biotech on innovative drug discovery technology to provide clients with the new generation of AI-based DNA Encoded compound library (Intelligent DEL, iDEL) screening technology platform for screening tumors and lead compounds for a series of specific targets in the field of neurological, autoimmune and other diseases.